Vincristine (NSC-67574) sulfate

For research use only. Not for use in humans.

目录号：S1241 别名： Leurocristine, Oncovin, 22-Oxovincaleukoblastine 中文名称：硫酸长春新碱

Vincristine (NSC-67574) sulfate Chemical Structure

CAS No. 2068-78-2

Vincristine sulfate (NSC-67574, Leurocristine, Oncovin, 22-Oxovincaleukoblastine)通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。Vincristine sulfate可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 734.41	现货
10mg	RMB 582.05	现货
50mg	RMB 2229.59	现货
200mg	RMB 7118.45	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Vincristine (NSC-67574) sulfate发表文献89篇：

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Theranostics, 2021, 11(9):4281-4297

PubMed: 33754061 ( click the link to review the publication )

Cell Rep, 2021, 36(11):109718

PubMed: 34525361 ( click the link to review the publication )

Cell Rep, 2021, 35(13):109302

PubMed: 34192534 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):97

PubMed: 34315482 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E361

PubMed: 33478100 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):789

PubMed: 34385422 ( click the link to review the publication )

Mol Cancer Ther, 2021, 10.1158/1535-7163.MCT-20-0864

PubMed: 33850006 ( click the link to review the publication )

J Neurochem, 2021, 156(5):642-657

PubMed: 32654140 ( click the link to review the publication )

Chemosphere, 2021, S0045-6535(21)03256-2

PubMed: 34742755 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01003-3

PubMed: 33475937 ( click the link to review the publication )

Chem Biol Interact, 2021, 340:109448

PubMed: 33775687 ( click the link to review the publication )

Toxicol Lett, 2021, 340:67-76

PubMed: 33429010 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2021, gmab101

PubMed: 34363072 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00639-4

PubMed: 34731453 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2021, mcs.a006049

PubMed: 33722797 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-1315

PubMed: 32826328 ( click the link to review the publication )

Oncogene, 2020, 39(17):3555-3570

PubMed: 32123312 ( click the link to review the publication )

Environ Sci Technol, 2020, 54(23):15267-15276

PubMed: 33201683 ( click the link to review the publication )

Cancer Lett, 2020, 469:111-123

PubMed: 31639426 ( click the link to review the publication )

J Pathol, 2020, 10.1002/path.5591

PubMed: 33206391 ( click the link to review the publication )

BMC Biol, 2020, 22;18(1):42

PubMed: 32321486 ( click the link to review the publication )
Arch Toxicol, 2020, 10.1007/s00204-020-02933-w

PubMed: 33057863 ( click the link to review the publication )

Mol Cancer Ther, 2020, 25;molcanther.1021.2019

PubMed: 32451331 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(23):24424-24440

PubMed: 33291076 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 17;14(4):e0008224

PubMed: 32302296 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxicology, 2020, 429:152329

PubMed: 31733235 ( click the link to review the publication )

Vet Comp Oncol, 2020, 10.1111/vco.12656

PubMed: 33025640 ( click the link to review the publication )

Biol Open, 2020, bio.050211

PubMed: 33372065 ( click the link to review the publication )

Cell Biol Int, 2020, 44(2):610-620

PubMed: 31743535 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Med Rep, 2020, 22(4):2791-2800

PubMed: 32945456 ( click the link to review the publication )

Neuroreport, 2020, 31(3):197-204

PubMed: 31834144 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

Int J Med Sci, 2020, 17(11):1652-1664

PubMed: 32669967 ( click the link to review the publication )

Cancer Res, 2019, 79(20):5382-5393

PubMed: 31405846 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Rep, 2019, 26(6):1544-1556

PubMed: 30726737 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 31742555 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )
Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6175

PubMed: 31817853 ( click the link to review the publication )

J Cell Biochem, 2019, 120(10):17791-17810

PubMed: 31264739 ( click the link to review the publication )

Oncotarget, 2019, 10(60):6403-6417

PubMed: 31741706 ( click the link to review the publication )

J Exp Med, 2018, 215(8):2137-2155

PubMed: 30045945 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1070

PubMed: 30341283 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

SLAS Discov, 2018, 23(7):687-696

PubMed: 29865911 ( click the link to review the publication )

J Exp Med, 2018, 215(12):3094-3114

PubMed: 30404791 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Clin Cancer Res, 2017, 15;23(10):2506-2515

PubMed: 27780854 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(8):1555-1565

PubMed: 28522589 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )
Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(24):39064-39076

PubMed: 28388564 ( click the link to review the publication )

Drugs R D, 2017, 17(2):287-296

PubMed: 28299646 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245981 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )

ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Int J Anal Chem, 2015, 2015:743915

PubMed: 27034675 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述

Vincristine sulfate (NSC-67574, Leurocristine, Oncovin, 22-Oxovincaleukoblastine)通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。Vincristine sulfate可诱导凋亡。

靶点

Microtubules ^[1]
(Cell-free assay)

32 μM

体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用，K_i为85 nM。^[1]在低浓度时，Vincristine抑制纺锤体，使染色体分离失败，进而导致中期停滞，并抑制有丝分裂。在较高浓度时，Vincristine可能干扰且诱导全部微管解聚。^[2] Vincristine 诱导肿瘤细胞凋亡，且抑制SH-SY5Y细胞增殖，IC50为0.1 µM。Vincristine诱导有丝分裂停滞，促进caspase-3和-9及cyclin B的表达，但降低cyclin D的表达。^[3] Vincristine通过干扰微管功能而诱导神经毒性形成，这会导致轴突运输堵塞，从而导致轴突变性。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	M1LOT2NmdGxiVnnhZoltcXS7IFHzd4F6	NXHPfYZqOC1yLkWg{txO	MkS5NlQhcA>?		NGrSdJRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	M4f0[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	NHfmVotCeG:ydH;zbZMhSXO\|YYm=	MXewMVAvPSEQvF2=	Ml3sNlQhcA>?		NYm4VI9McW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NYryNldXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2.2.15	MlH5SpVv[3Srb36gRZN{[Xl?	M4DTOlAvOSEQvF2=	MW[yOEBp		MkHMdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO\|aX;u	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	MlS1SpVv[3Srb36gRZN{[Xl?	MXywMlEh\|ryP	MonRNlQhcA>?		NGLZdolxem:vb4Tld{Bp\XCjdHn0bZMhSiC4aYL1d{Bxem:2ZXnuJIV5eHKnc4Ppc44>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	Mni3SpVv[3Srb36gRZN{[Xl?	MnrZNE4yKM7:TR?=	NHzKOWU1QCCq		NFLk[Ihxem:vb4Tld{Bk\WyuIHX4Z5JmfGmxbjDv[kBp\XCjdHn0bZMhSiC4aYL1d{BvfWOuZX;jZZB{cWS\|IHnud5Rm[WRib3[gbIVx[XSrdHnzJGIhfmm{dYOgSIFv\SCyYYL0bYNt\XN?	NHryT449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2N\|c3QSd-MkW2OlM4Pjl:L3G+
HepG2-HBV1.1	NF3DT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYf3V3VUOC5zIN88US=>	M3j5PVEuPSCm		MUPpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	M2r0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVewMlEh\|ryP	NF[0e3MyNTViZB?=		NWDtWnFicW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=>	NYi3NW9xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2-HBV1.1	MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkOxNE4yKM7:TR?=	MV2xNk04OiCq		NEKw[W5qdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>	M1PON\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWS1N\|JoOC5zIN88US=>	MoXUNVIuPzJiaB?=		MVPpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W=	MnjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NkO3OlkoRjJ3Nk[zO\|Y6RC:jPh?=
Raji	NXrVc\|l3TnWwY4Tpc44hSXO\|YYm=	NYCwNnBUOC53wrFOwG0>	MlXZO\|IhcA>?		MYDhZo9tcXOqZYOgZZV1d3CqYXf5xsA>	NGLEWWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OlM4Pyd-MkW0OFY{Pzd:L3G+
SK-MEL-28	Mo\aSpVv[3Srb36gRZN{[Xl?	NWPHPGZ{OzBibl2=	MlTROkBp		MXHpcoR2[2W\|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>?	NF3wUJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOxN\|AyOCd-MkWzNVMxOTB:L3G+
H157	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFwMEOgxtEhOC5yNDDtbZUzVQ>?	NYDkOWJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOVc6OTFpPkK1NlU4QTFzPD;hQi=>
Jurkat	NFLxSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnz0NU0{KG6P	NWHncJh[PDkEoHi=	Ml[0SG1UVw>?	NHTtR2Nl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6	NInqWoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1OlE1Pid-MkWxOVYyPDZ:L3G+
CEM	Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYG3RWo3OS1\|IH7N	MkCyOFjDqGh?	M{O3OWROW09?	MlLG[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NF64bJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1OlE1Pid-MkWxOVYyPDZ:L3G+
P12	M2q3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjxcJIyNTNibl2=	MXe0POKhcA>?	M3PMVWROW09?	NGrzWnpl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3NkG0Okc,OjVzNU[xOFY9N2F-
KB	MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF:5ZmlKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN	M4L5flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEW4OVI3Lz5{NUC1PFUzPjxxYU6=
KBv200 (ABCB1)	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTBwM{S2NkDDuSByLkCwOlYh\|ryP	M4S0T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEW4OVI3Lz5{NUC1PFUzPjxxYU6=
SUDHL6	NUnnW3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3CTYMy6oDLzszN	M4CwSFQ5Nzd{IHi=		NWfhUJBVcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	MlfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NkG2NFQoRjJ2OU[xOlA1RC:jPh?=
SUDHL6	NXXuSHl7TnWwY4Tpc44hSXO\|YYm=	MWKx5qCK\|ryP	M{\re\|czKGh?		M132e4lv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF?	NFjjeIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NVYxPCd-MkS5OlE3ODR:L3G+
HCT-116	NYDDV\|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPHTVUxRTVibl2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{N{i1O{c,OjR7Mke4OVc9N2F-
SKNBe2C	NIH5TmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXSzWIdmUUN3ME2zNk45yrF2LkCgcm0>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{MUmyNEc,OjR7MkG5NlA9N2F-
IGNR91	MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnWTWM2OD1{ND6zxtEyNjdibl2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{MUmyNEc,OjR7MkG5NlA9N2F-
SKNAS	NVGzcIVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTFwNdMxNE4zKG6P	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{MUmyNEc,OjR7MkG5NlA9N2F-
LAN1	M2Pudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTJwM9MxNE4zKG6P	MnP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkG5NlAoRjJ2OUKxPVIxRC:jPh?=
SHSY5Y	NW\TUmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlj5TWM2OD16LkNCtVAvPiCwTR?=	MnG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkG5NlAoRjJ2OUKxPVIxRC:jPh?=
A549-WT	NXnEOnoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjwbopKSzVyPUG5MlQ{PyEEsTCwMlU6PCBibl2=	NWDnZVNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
A549-R	M2HEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILJd2xKSzVyPUGyMlE4QCEEsTCwMlM{OyBibl2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3OEiyO{c,OjR6NUi4Nlc9N2F-
MCF-7-WT	M2jo[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf1NJhKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3OEiyO{c,OjR6NUi4Nlc9N2F-
MCF-7-R	NUDKdXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDtNXZKSzVyPUWuOVM6KMLzIECuNVQ1KCCwTR?=	NHfDU449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1PFgzPyd-MkS4OVg5Ojd:L3G+
A549-R	MX;DfZRwfG:6aXPpeJkhSXO\|YYm=				NX;QeGhJUUN3ME2xNk4yPzhiwsGgNE4{OzNibl2=	NWjVUHEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
MCF-7-R	M{W3eGN6fG:2b4jpZ4l1gSCDc4PhfS=>				MV\JR\|UxRTVwNUO5JOKyKDBwMUS0JI5O	NXn1RXVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg5OjdpPkK0PFU5QDJ5PD;hQi=>
SW620	Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkSyTWM2OD15LkiwJOKyKDBwMEigcm0>	MlTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mk[3N\|koRjJ2N{K2O\|M6RC:jPh?=
SW620/AD300	M4ftR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTV[ZlKSzVyPUmwPU43OCEEsTC4MlkyKG6P	MmnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mk[3N\|koRjJ2N{K2O\|M6RC:jPh?=
HEK293/pcDNA3.1	NWPtTWlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nqcmlEPTB;MT60OUDDuSByLkKwJI5O	M{X4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K2O\|M6Lz5{NEeyOlc{QTxxYU6=
HEK293/ABCC1	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXSfXFbUUN3ME2xPU4zQSEEsTCyMlA5KG6P	NVG5cZZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY4OzlpPkK0O\|I3PzN7PD;hQi=>
TCC	M1vWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Moj6NlQhcA>?		MVrJR\|UxRTdyIH7N	NI\CcJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEexOlk1PCd-MkS3NVY6PDR:L3G+
TCC	NGLYTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{LhdVQ5KGh?		Mo\NTWM2OD13MDDuUS=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDdzNkm0OEc,OjR5MU[5OFQ9N2F-
HepG2/ADM	NWXP[GN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jrSmlEPTB;Mj63PFY{yrFyLkKzO\|Eh\|ryP	M17GR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{C0OVU3Lz5{NEewOFU2PjxxYU6=
HepG2	NVjWVpNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLNTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1?	M{C1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{C0OVU3Lz5{NEewOFU2PjxxYU6=
MCF-7/ADR	NF\hNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moj5TWM2OD12LkS4NlbDuTBwMkC3NEDPxE1?	NGG0Smg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOFU2Pid-MkS3NFQ2PTZ:L3G+
MCF-7	M2TVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7wcJNxUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2=	NEXpclE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOFU2Pid-MkS3NFQ2PTZ:L3G+
A-172	NH:1fFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnYS3oxNjIEoN88US=>	M3HqSVI1Nzd{IHi=		Ml\NbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	NEDz[4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFI{PSd-MkS1N\|AzOzV:L3G+
U-251MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2wMlHDqM7:TR?=	NGCzSWQzPC95MjDo		NFX2fWRqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6	M1[5eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwNlM2Lz5{NEWzNFI{PTxxYU6=
DLD-1	M1fqU2Z2dmO2aX;uJGF{e2G7	MXOxNFAhdk1?	MYi0PEBp		MXnwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA>	M1;KcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NECzOFU{Lz5{NESwN\|Q2OzxxYU6=
CCD18Co	M2PaNGZ2dmO2aX;uJGF{e2G7	M{TiRlExOCCwTR?=	M4TGb\|Q5KGh?		MluzdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh	Ml7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEO0OVMoRjJ2NECzOFU{RC:jPh?=
DLD-1	NUnIcYVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjsZVdWOC1zMECwJI5O	MWm0PEBp		NGW0VYZqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyM{S1N{c,OjR2MEO0OVM9N2F-
CCD18Co	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXVNE0yODByIH7N	M3XLXlQ5KGh?		NXrySnRWcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	NXTvNHdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFM1PTNpPkK0OFA{PDV\|PD;hQi=>
HepG2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NITEXlYzPCCq		M1:1VWlEPTB;NUKuOgKBkc7:TR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN2MU[4PEc,OjR\|NEG2PFg9N2F-
HEK293/pcDNA3.1	Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLITWM2OD1yLkCwOOKyOC5yMECzJO69VQ>?	M3TVclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki0O\|g{Lz5{NEK4OFc5OzxxYU6=
HEK293/MRP1	M1jIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTBwMEW1xtExNjBzMkCg{txO	M{HmXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki0O\|g{Lz5{NEK4OFc5OzxxYU6=
Ramos	NFjzNlhCeG:ydH;zbZMhSXO\|YYm=	M3j1c\|LjiIoQvF2=	NGrZZoo1QCCq		MXzpcoR2[2W\|IEO0MlYmyrFzLkmyKUBieG:ydH;zbZM>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3NkS5NUc,OjR{NU[0PVE9N2F-
NCI-H1299/pcDNA3	NEXMSGFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M{C4UlAuOjBibl2=	MVq5OkBp		MmjTbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	Ml\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{ewNVIoRjJ2MUe3NFEzRC:jPh?=
H1299/ICAM-3	MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NWr6OJllOC1{MDDuUS=>	NFnmOmQ6PiCq		NF;TTJlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M{\3OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe3NFEzLz5{NEG3O\|AyOjxxYU6=
NCI-H1299/pcDNA3	NH[zeGNHfW6ldHnvckBCe3OjeR?=	NYKzdll6OS93L{GwM\|IxyqCwTR?=	NWjRU3l1QTZiaB?=		NYfKNpd6cW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1\|LDC4MEA6NCCjbnSgVGFTWA>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5N{CxNkc,OjRzN{ewNVI9N2F-
H1299/ICAM-3	MX3GeY5kfGmxbjDBd5NigQ>?	NWjISopOOS93L{GwM\|IxyqCwTR?=	MWe5OkBp		NVnEb3N3cW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1\|LDC4MEA6NCCjbnSgVGFTWA>?	M{TFcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe3NFEzLz5{NEG3O\|AyOjxxYU6=
W1	NWTGXWFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFziU5FKSzVyPUCuNFA{OiEQvF2=	M37LblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUSwNVc3Lz5{NEG0NFE4PjxxYU6=
W1VR	M{PZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTBwMEW2JO69VQ>?	NYDqU4tXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFAyPzZpPkK0NVQxOTd4PD;hQi=>
K562	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LaWmlEPTB;MD6wN\|IhyrFiMD6wNFEhKM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|NUmzO{c,OjRzM{W5N\|c9N2F-
K562/ADR	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvYTWM2OD1\|LkK2NUDDuSByLkSxNkDPxE1?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|NUmzO{c,OjRzM{W5N\|c9N2F-
K562	M2PTWWFxd3C2b4Ppd{BCe3OjeR?=	NGPR[JoxNjNizszN	Ml\2NlQhcA>?		NXTQcJNWcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	NF\NZpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOVk{Pyd-MkSxN\|U6Ozd:L3G+
K562/ADR	MYnBdI9xfG:\|aYOgRZN{[Xl?	NW\Tb3BpOyEQvF2=	NYTMdZk{OjRiaB?=		MX3pcoR2[2W\|IHHwc5B1d3Orcx?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|NUmzO{c,OjRzM{W5N\|c9N2F-
A549	M3\U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfFSY5KSzVyPUCuNVAhyrFiMD6wN{DPxE1?	NWPsfW82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5O\|ExPzVpPkKzPVcyODd3PD;hQi=>
K562	MnLRR4VtdCCYaXHibYxqfHliQYPzZZk>	NEH0Z5E{Njd34pETOlDDqG6P	MnnJO\|LDqGkEoB?=		MWPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	M4i0NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEe3NlI{Lz5{M{i3O\|IzOzxxYU6=
lucena	MlvOR4VtdCCYaXHibYxqfHliQYPzZZk>	MUWzMlc26oDVNkFCpI5O	M3:4PVczyqCqwrC=		NX;aT3Fudm9iZX\m[YN1	NFzLNIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|IzOyd-MkO4O\|czOjN:L3G+
FEPS	NU\JU3BuS2WubDDWbYFjcWyrdImgRZN{[Xl?	M3XwNVMvPzYkgKO2NOKhdk1?	M{m5WFczyqCqwrC=		NGrNU4pvdyCnZn\lZ5Q>	MnzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{eyNlMoRjJ\|OEe3NlI{RC:jPh?=
A2780	M3i1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHy5R4dKSzVyPUOuOUBuVQ>?	NE\TNow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVIxOyd-MkO4NlkzODN:L3G+
ACHN	NEHHTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Xad2lEPTB:MD6xJI1O	NHTX[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVIxOyd-MkO4NlkzODN:L3G+
U-937	NVfiXGdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoG3TWM2ODx\|NDDuUS=>	NE\6bm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVIxOyd-MkO4NlkzODN:L3G+
Jurkat	M{jYN2Fxd3C2b4Ppd{BCe3OjeR?=	NFm1[lQ2yqEQvHevcYzDqA>?	NVnZdHBOOjRiaB?=		NXvFb4t1cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	M{KyUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEGwOFA6Lz5{M{ixNFQxQTxxYU6=
Jurkat	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPoWJA2yqEQvHevcYzDqA>?	MVmyOEBp		NYDodpZZ[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl	Moq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MUC0NFkoRjJ\|OEGwOFA6RC:jPh?=
Hep-2	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrSfYkxUUN3ME2wMlA1yrFyLkCxJO69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd6MESyOEc,OjN5OEC0NlQ9N2F-
Hep-2/v	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjRTWM2OD1zLklCtVAvOjBizszN	M3[2O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{iwOFI1Lz5{M{e4NFQzPDxxYU6=
SGC-7901	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37Eb\|AuOTBizsznM41t	NEHTS5AzPC92OD:3NkBp		MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MnPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEO1O\|IoRjJ\|N{SzOVczRC:jPh?=
SGC-7901/VCR	MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\4N\|g2OC1zMDFOwIcwdWx?	M{TZWFI1NzR6L{eyJIg>		NE\DZXlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	Mn7QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEO1O\|IoRjJ\|N{SzOVczRC:jPh?=
SGC-7901	NHzoR3pCeG:ydH;zbZMhSXO\|YYm=				MXrpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	M{\DS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SzOVczLz5{M{e0N\|U4OjxxYU6=
SGC-7901/VCR	NYPNS\|J6SXCxcITvd4l{KEG\|c3H5				NV;LT2RXcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	NWLZSJYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFM2PzJpPkKzO\|Q{PTd{PD;hQi=>
KB-3-1	M2XFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF75cYFKSzVyPUGuOlYhyrFiMD6xOlIh\|ryP	M{nMNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkezOFQ2Lz5{M{[3N\|Q1PTxxYU6=
KB-C2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPOTWM2OD1{MEKuOVYhyrFiNEKuOFgyKM7:TR?=	NXjxU5BIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|M1PDVpPkKzOlc{PDR3PD;hQi=>
KB-3-1	NUTEbJBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\aXWlEPTB;MT6yOkDDuSByLkCyO{DPxE1?	M{K0OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkezOFQ2Lz5{M{[3N\|Q1PTxxYU6=
KB-V1	M1S5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTwc2RLUUN3ME2yNFgvQDViwsGgNlAvPCEQvF2=	NH3GUI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3N\|Q1PSd-MkO2O\|M1PDV:L3G+
HEK293/pcDNA3.1	M2XPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fFb2lEPTB;MkSuNUDDuSByLkKwOEDPxE1?	NGXC[IM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3N\|Q1PSd-MkO2O\|M1PDV:L3G+
HEK293/ABCB1	NWD4SlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4n1[WlEPTB;M{WxNk45KMLzIEO3PE4{QTFizszN	NXfj[YVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|M1PDVpPkKzOlc{PDR3PD;hQi=>
A549/EGFP	NX;HWWw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWwMlAyNTFyMECg{txO			M3;aOmlEPTB;OE[uO{DDuSB{OT6xJO69VQ>?	M{HLbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkO0NlgzLz5{M{[zOFI5OjxxYU6=
A549/Slug	NGPZNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWewMlAyNTFyMECg{txO			Ml3iTWM2OD17LkegxtEhOy5zIN88US=>	M{i5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkO0NlgzLz5{M{[zOFI5OjxxYU6=
JFCR39	M2HNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzzdIoyKML3TR?=	MoXwNlQhcA>?	NVH5PJA3TE2VTx?=	NFzNXJBu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy\|	Mnm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OUiyO\|YoRjJ\|NUm4Nlc3RC:jPh?=
A549	Mkf3SpVv[3Srb36gRZN{[Xl?	NVzPUFZQOTByIH7N	NUP1eYVTOTZiaB?=	MlK4SG1UVw>?	MkHNcIVi\HNidH:gZUBtd3O\|IH;mJI1q[3KxdIXieYxmew>?	MmD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OUiyO\|YoRjJ\|NUm4Nlc3RC:jPh?=
SGC7901	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTFwMkdihKnDueLCiUCuNVEh\|rypL33s	MkLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/LV-NC	NUfNRnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvXTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=>	NVTZfppwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/LV-SGO1	NGft[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnpe3BKSzVyPUSuN\|bjiIoEsfMAjVAvOzdizsznM41t	M3TzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/VCR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{n6WmlEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NES4Nkc,OjN3NkS0PFI9N2F-
SGC7901/VCR-NC	MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NED0eGtKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>?	M1nzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SGC7901/VCR-si-SGO1	M4DuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TkemlEPTB;Nj6xPQKBkcLz4pEJNU4xOyEQvHevcYw>	MkXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/ADR	M2eySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4n6UGlEPTB;Nz64OgKBkcLz4pEJNE43PCEQvHevcYw>	MlTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/ADR-NC	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknITWM2OD16Lkmz5qCKyrIkgJmwMlY5KM7:Zz;tcC=>	MkjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/ADR-si-SGO1	NGLWN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;OT2EzUUN3ME2zMlQ36oDLwsJihKkxNjJ7IN88[{9udA>?	M{DDXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[0OFgzLz5{M{W2OFQ5OjxxYU6=
SH-SY5Y	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGe1XGkxNjByMT2xNEDPxE1?	MV2yOEBp		MVrJR\|UxRTBwMUGzxtExNjBzMjFOwG0>	NWTO[\|hKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlkxPjVpPkKzNVI6ODZ3PD;hQi=>
SH-SY5Y	M{PiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;MNE4xODFvMUCg{txO	M3nSflQ5KGh?		MXzJR\|UxRTBwMEe4xtExNjByOTFOwG0>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF{OUC2OUc,OjNzMkmwOlU9N2F-
SH-SY5Y	M3n6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;VflAvODBzLUGwJO69VQ>?	M3j5TFczKGh?		NX\ufIZ3UUN3ME2wMlA2OcLzMD6wNFgh\|ryP	NYXrR3JmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlkxPjVpPkKzNVI6ODZ3PD;hQi=>
SH-SY5Y	NYHXOYxLSXCxcITvd4l{KEG\|c3H5	MXqwMlEh\|ryP	NX[xS2dtOC1{NDDo		MULpcoR2[2W\|IHHwc5B1d3OrczDv[kBUUC2VWUXZJINmdGy\|IH\vcIxwf2mwZzDj[YxtKGO7Y3zlJIFzemW\|dDDheEB1cGViR{KvUUBxcGG\|ZR?=	M4i0O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUK5NFY2Lz5{M{GyPVA3PTxxYU6=
SH-SY5Y	MYLBdI9xfG:\|aYOgRZN{[Xl?	MXywMlEh\|ryP	M{fWe\|AuOjRiaB?=		NGTNSJVqdmS3Y3XzJI1qfG:2aXOgZZJz\XO2wrC=	M4Ozd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUK5NFY2Lz5{M{GyPVA3PTxxYU6=
LNCAP	NW\VXmpZS3m2b4TvfIlkcXS7IHHzd4F6		M4q2S\|czKGi{cx?=		M33OVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvODB{OTFOwG0v	M{LzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyN{OyPFA6Lz5{MEezNlgxQTxxYU6=
LNCAP	NGW1NpZEgXSxdH;4bYNqfHliYYPzZZk>		NXywZYdTPzJiaILz		Mn7lR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xODZzIN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJzNUO0PEc,OjN{MUWzOFg9N2F-
PC3	NFfh[ZhEgXSxdH;4bYNqfHliYYPzZZk>		MkPtO\|IhcHK\|		MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wNVEh\|ryPLh?=	M4H3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyN{OyPFA6Lz5{MEezNlgxQTxxYU6=
PC3	M2XwZ2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NYPxS\|RqPzJiaILz		M1\JOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCwMlAyPSEQvF2u	M2K3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkG1N\|Q5Lz5{M{KxOVM1QDxxYU6=
PC3	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		MoXUO\|IhcHK\|		NHHQTVlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSByLkCxOVMh\|ryPLh?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OUK5NUc,OjN2OEmyPVE9N2F-
NFF	MlO2R5l1d3SxeHnjbZR6KGG\|c3H5		MlzPO\|IhcHK\|		MmDrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmZHKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC5yMU[5JO69VS5?	MlHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEmyPVEoRjJ\|NEi5NlkyRC:jPh?=
NFF	M2L3b2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NGnMflQ4OiCqcoO=		MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOSmYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wNVch\|ryPLh?=	NIWzT2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KxOVM1QCd-MkOyNVU{PDh:L3G+
A549	NFX4NJBEgXSxdH;4bYNqfHliYYPzZZk>		MYK3NkBpenN?		MkjhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJzNUO0PEc,OjN{MUWzOFg9N2F-
KB	NETCbm5EgXSxdH;4bYNqfHliYYPzZZk>		NHnYNIE4OiCqcoO=		MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV{Mkm1N{c,OjZ3MkK5OVM9N2F-
PC3	M1jOZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXvjcHp1PDhiaILz		M3LneWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyO\|Yh\|ryPLh?=	M3HuclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4N\|I{Lz5{OECzPFMzOzxxYU6=
HEK	NWLtXGp7S3m2b4TvfIlkcXS7IHHzd4F6		NEHLVGI4OiCqcoO=		NXvVOmpyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEWNIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvODNzIN88UU4>	M1;0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkG1N\|Q5Lz5{M{KxOVM1QDxxYU6=
HeLa	NHPmSYdEgXSxdH;4bYNqfHliYYPzZZk>		M3T1OVczKGi{cx?=		M2[4OmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSByLkCzOVgh\|ryPLh?=	M{TPPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5NlkyLz5{M{S4PVI6OTxxYU6=
HeLa	NYOxS4RxS3m2b4TvfIlkcXS7IHHzd4F6		MlvFO\|IhcHK\|		M3\NVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xOzZizszNMi=>	NG\FeWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KxOVM1QCd-MkOyNVU{PDh:L3G+
BT549	NHnvUWpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFfMe3o1QCCqcoO=		M2ewd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFU1PzJizszNMi=>	MlH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{izNlMoRjJ6MEO4N\|I{RC:jPh?=
DU145	NUPwfGZQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUD6UHNtPDhiaILz		MkG5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCGVUG0OUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wO\|I{KM7:TT6=	MmXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{izNlMoRjJ6MEO4N\|I{RC:jPh?=
Leukemia cells	Mn;6RY51cXS3bX;yJIF{e2G7		M{XlbFQ5KGi{cx?=		MkTPRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTHX1b4VucWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvOSEQvF2u	M3S0NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
Leukemia cells	M{mwRWFvfGm2dX3vdkBie3OjeR?=		MUO0PEBpenN?		MmnMRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTHX1b4VucWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlEh\|ryPLh?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Colon cancer cells	NV;0WIVnS3m2b4TvfIlkcXS7IHHzd4F6				NFjWSJpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMtKEeLNUCgQUAxNjFizszNMi=>	MnnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
Leukemia cells	MnfXR5l1d3SxeHnjbZR6KGG\|c3H5				NEDBO2JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBt\XWtZX3pZUBk\WyuczygS2k2OCB;IECuNUDPxE1w	NYDEOZZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
Colon cancer cells	MlnSRY51cXS3bX;yJIF{e2G7		MVW0PEBpenN?		NUnYT3VbSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gR49td25iY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlEh\|ryPLh?=	MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
Colon cancer cells	NX7LTJIxSW62aYT1cY9zKGG\|c3H5		Mk[5OFghcHK\|		M33pSGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPvcI9vKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTUA:KDBwMTFOwG0v	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Leukemia cells	NGDkWJhCdnSrdIXtc5Ih[XO\|YYm=				NFz6NYdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBt\XWtZX3pZUBk\WyuczygS2k2OCB;IECuNUDPxE1w	NXL1bHRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
Colon cancer cells	MnXLRY51cXS3bX;yJIF{e2G7				MXHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDjc4xwdiC2dX3vdkBk\WyuczygS2k2OCB;IECuNUDPxE1w	Mlq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
Leukemia cells	NIrZSYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFXRZY01QCCqcoO=		NHzVR5hIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBt\XWtZX3pZUBk\WyuczDh[pRmeiB2ODDodpMtKEeLNUCgQUAxNjFizszNMi=>	MlHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
Colon cancer cells	NYPhNnY6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH\tfYo1QCCqcoO=		NWS0VY5{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNUDPxE1w	NIPIXVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
Leukemia cells	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		NGD0XYs1QCCqcoO=		NWfkW49iS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zIN88UU4>	NYjQ[od3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
Colon cancer cells	MnXmR5l1d3SxeHnjbZR6KGG\|c3H5		NV3qdlB6PDhiaILz		NEeyS5JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6xJO69VS5?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
Leukemia cells	NHjUe3hEgXSxdH;4bYNqfHliYYPzZZk>		M2nSXFQ5KGi{cx?=		NUm3UnlTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zIN88UU4>	MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
Colon cancer cells	NI\RU3lEgXSxdH;4bYNqfHliYYPzZZk>		NUfyUpJFPDhiaILz		NE\5OG5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEV0yRTjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlEh\|ryPLh?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
MDA-MB-231	NUjvWVZ[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1XEeVQ5KGi{cx?=		NFW5[XhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUG2OkDPxE1w	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEOyN{c,OjhyM{izNlM9N2F-
central nervous system cancer cells	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=				Mnz3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ4VvfHKjbDDu[ZJ3d3W\|IIP5d5RmdSClYX7j[ZIh[2WubIOsJGdKPTBiPTCwMlEzPTh7IN88UU4>	M4XUeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
prostate cancer cells	NGG2[5REgXSxdH;4bYNqfHliYYPzZZk>				NXW5N5NrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|LDDHTVUxKD1iMD6xNlU5QSEQvF2u	NHvCNpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
CNS	NH;JZmVCdnSrdIXtc5Ih[XO\|YYm=		NWLSVo1vPDhiaILz		MorzRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ17TJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwJF0hOC5zMkW4PUDPxE1w	Mny0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
prostate cancer cells	NIjQeZdCdnSrdIXtc5Ih[XO\|YYm=		MUG0PEBpenN?		NEH5VVNCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvOTJ3OEmg{txONg>?	NV\FPGxDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
CNS	MmLHRY51cXS3bX;yJIF{e2G7				NXvHN5ZZSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhS06VIIT1cY9zKGOnbHzzMEBIUTVyIE2gNE4yOjV6OTFOwG0v	M2X4SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
prostate cancer cells	MljERY51cXS3bX;yJIF{e2G7				MkL2RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgdJJwe3SjdHWgeJVud3JiY3XscJMtKEeLNUCgQUAxNjF{NUi5JO69VS5?	NG[1No49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
CNS	M2Ttc2FvfGm2dX3vdkBie3OjeR?=		NXvmO4hLPDhiaILz		NVvaO3d4SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gR25UKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTUA:KDBwMUOg{txONg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
prostate cancer cells	MXrBcpRqfHWvb4KgZZN{[Xl?		MoHNOFghcHK\|		NITUdlFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlE{KM7:TT6=	NV;wWZFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
prostate cancer cells	M3HuUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUW0PEBpenN?		NESzcolIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBxem:\|dHH0[UBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yOyEQvF2u	NYHYPW5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
CNS	Mkn3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVzKV203PDhiaILz		NEDabWVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBEVlNiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwMUOg{txONg>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
CNS	M325NmN6fG:2b4jpZ4l1gSCjc4PhfS=>		Ml;zOFghcHK\|		NWn1cGI3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkGzJO69VS5?	NIXLTVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
prostate cancer cells	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		NVH5N\|JrPDhiaILz		MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6xN{DPxE1w	NVTDfWs{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
prostate cancer cells	MmDTR5l1d3SxeHnjbZR6KGG\|c3H5		NEm0NlU1QCCqcoO=		Mk\nR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNVMh\|ryPLh?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
CNS	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		MmPJOFghcHK\|		M2\pWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNPWyClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zMzFOwG0v	NVfXZopCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
Melanoma cells	NVzyVY5ESW62aYT1cY9zKGG\|c3H5		NEXsemY1QCCqcoO=		MmP6RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTXXsZY5wdWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvOTV6NEmg{txONg>?	NYHnVlJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
Melanoma cells	M{PP[2N6fG:2b4jpZ4l1gSCjc4PhfS=>				M{TTSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|LDDHTVUxKD1iMD6xOVg1QSEQvF2u	NVezV5hkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
Melanoma cells	MmrYRY51cXS3bX;yJIF{e2G7				M3zqVGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1mdGGwb33hJINmdGy\|LDDHTVUxKD1iMD6xOVg1QSEQvF2u	M2fwblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
Melanoma cells	NYjwfI5NSW62aYT1cY9zKGG\|c3H5		NF3adGo1QCCqcoO=		M2T1eGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3lcIFvd22jIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLIE2gNE4yPiEQvF2u	NEe2WHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Melanoma cells	NF7EToNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				Mnm0S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gcYVt[W6xbXGgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yPiEQvF2u	MmrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
Melanoma cells	NYLucXJrS3m2b4TvfIlkcXS7IHHzd4F6		NHfSO481QCCqcoO=		NF64UoREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk\WyuczDh[pRmeiB2ODDodpMtKEeLNUCgQUAxNjF4IN88UU4>	NEjIPHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
Melanoma cells	MoHoR5l1d3SxeHnjbZR6KGG\|c3H5		MYe0PEBpenN?		M{nRfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTZizszNMi=>	MlHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
A549	NV7HZlJTSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoDiOFghcHK\|		MofZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkG3NVUh\|ryPLh?=	NYXEd4xvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g{OjNpPkK4NFM5OzJ\|PD;hQi=>
NSCLC	NIr4[nlCdnSrdIXtc5Ih[XO\|YYm=		MlTvOFghcHK\|		NFixeHBCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUSB;IECuNlUh\|ryPLh?=	M2q5b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
NSCLC	MmG3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1jDR\|Q5KGi{cx?=		NULzSJAyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVlOFTFOgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4zPSEQvF2u	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
NSCLC	MlLTR5l1d3SxeHnjbZR6KGG\|c3H5		NIr1Zng1QCCqcoO=		MnSwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6yOUDPxE1w	MnjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
NSCLC	MnjHR5l1d3SxeHnjbZR6KGG\|c3H5		NGLwfpc1QCCqcoO=		NUHjV\|ZSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVlOFTFOgZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4zPSEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
NSCLC	M1rHe2FvfGm2dX3vdkBie3OjeR?=				M2TLSmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JG5US0yFIHPlcIx{NCCJSUWwJF0hOC5{NUGxPUDPxE1w	NXfhbZVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
NSCLC	M4HKcGFvfGm2dX3vdkBie3OjeR?=		MkniOFghcHK\|		MnPWRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTmPDUGMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNlUyOTlizszNMi=>	NHPhVHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Non-small cell lung carcinoma cells	M3rkcGN6fG:2b4jpZ4l1gSCjc4PhfS=>				MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOc44ue22jbHygZ4VtdCCudX7nJINiemOrbn;tZUBk\WyuczygS2k2OCB;IECuNlUyOTlizszNMi=>	NITnN5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
ovarian cancer cells	MnW3R5l1d3SxeHnjbZR6KGG\|c3H5				MknIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gc5ZiemmjbjDjZY5k\XJiY3XscJMtKEeLNUCgQUAxNjNzNkKzJO69VS5?	NWjHW4p6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
renal cancer cells	NELVd\|lEgXSxdH;4bYNqfHliYYPzZZk>				NIW2UmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBz\W6jbDDjZY5k\XJiY3XscJMtKEeLNUCgQUAxNjNzNkKzJO69VS5?	NU\OU4N[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
breast cancer cells	NILQfXlEgXSxdH;4bYNqfHliYYPzZZk>				M1X6NWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMtKEeLNUCgQUAxNjNzNkKzJO69VS5?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
ovarian cancer cells	M1vqd2FvfGm2dX3vdkBie3OjeR?=		NYHCNmZFPDhiaILz		NHvUZmdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4{OTZ{MzFOwG0v	Ml[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
renal cancer cells	NFPvNVVCdnSrdIXtc5Ih[XO\|YYm=		NFXySWk1QCCqcoO=		NH3mPJdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuN\|E3OjNizszNMi=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
breast cancer cells	NYXyeHFiSW62aYT1cY9zKGG\|c3H5		M3XGVlQ5KGi{cx?=		M4\zc2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLy[YF{fCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuN\|E3OjNizszNMi=>	MkfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
renal cancer cells	MVvBcpRqfHWvb4KgZZN{[Xl?				Mkn6RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgdoVv[WxidIXtc5Ih[2WubIOsJGdKPTBiPTCwMlMyPjJ\|IN88UU4>	M1X1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
ovarian cancer cells	NUTxelJbSW62aYT1cY9zKGG\|c3H5				MXnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDveoFzcWGwIIT1cY9zKGOnbHzzMEBIUTVyIE2gNE4{OTZ{MzFOwG0v	MlTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
breast cancer cells	MVHBcpRqfHWvb4KgZZN{[Xl?				NHKy[XFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBjemWjc4SgeJVud3JiY3XscJMtKEeLNUCgQUAxNjNzNkKzJO69VS5?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
ovarian cancer cells	NHzETXhCdnSrdIXtc5Ih[XO\|YYm=		Ml\4OFghcHK\|		MWjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCxdnHybYFvKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTUA:KDBwM{Kg{txONg>?	M{DidFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
renal cancer cells	NEn1UWFCdnSrdIXtc5Ih[XO\|YYm=		MUe0PEBpenN?		NWrFRodkSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKKD1iMD6zNkDPxE1w	NGO5VYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
breast cancer cells	Mm\1RY51cXS3bX;yJIF{e2G7		NHPEd\|k1QCCqcoO=		M4jTSWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLy[YF{fCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2khRSByLkOyJO69VS5?	NGq2bZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal cancer cells	NIfnUldIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEjFdI41QCCqcoO=		M{LCd2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	NH7OSlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
breast cancer cells	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnTNOFghcHK\|		Mmi3S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	NUPOXJJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
ovarian cancer cells	NV3yOVVlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlTLOFghcHK\|		MXnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPeoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
breast cancer cells	M4j5emN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3n3UVQ5KGi{cx?=		M2nxTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6zNkDPxE1w	MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
renal cancer cells	NWjBS\|FWS3m2b4TvfIlkcXS7IHHzd4F6		M2PWdFQ5KGi{cx?=		M{[3T2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	M1TKTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
ovarian cancer cells	MkfTR5l1d3SxeHnjbZR6KGG\|c3H5		NHTRWGU1QCCqcoO=		MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	MkO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
renal cancer cells	M4PTemN6fG:2b4jpZ4l1gSCjc4PhfS=>		MXG0PEBpenN?		Mn30R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwM{Kg{txONg>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
ovarian cancer cells	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		NUTGc\|NzPDhiaILz		MnvXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gc5ZiemmjbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6zNkDPxE1w	NG\UVoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
breast cancer cells	NWfxUpRwS3m2b4TvfIlkcXS7IHHzd4F6		NH\FT4Q1QCCqcoO=		M2rPZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6zNkDPxE1w	NHz2S489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
Lu1	MnvYR5l1d3SxeHnjbZR6KGG\|c3H5		M3jYeVczKGi{cx?=		MnPDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUJUyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlQ5KM7:TT6=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV{Mkm1N{c,OjZ3MkK5OVM9N2F-
MCF7	NUS3ZlF3S3m2b4TvfIlkcXS7IHHzd4F6		MXu3NkBpenN?		M3LrV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvPTFizszNMi=>	NUHxWlVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NlI6PTNpPkK2OVIzQTV\|PD;hQi=>
HepG2	M{f5PGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NF;id4c4OiCqcoO=		NY\0N41DS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwNkmg{txONg>?	NFnoSm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWyNlk2Oyd-Mk[1NlI6PTN:L3G+
COLON	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFrRUGQ1QCCqcoO=		Mk\FS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hOy57ODFOwG0v	NXTkO4I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
COLON	NH;MN5JEgXSxdH;4bYNqfHliYYPzZZk>		MnXGOFghcHK\|		NWf6W5p7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMz65PEDPxE1w	NID3VHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
COLON	M3XGd2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NGrDeWY1QCCqcoO=		NX7afoJLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0:OT16gZ4VtdHNiYX\0[ZIhPDhiaILzMEBVT0liPTCzMlk5KM7:TT6=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
COLON	M2mxO2N6fG:2b4jpZ4l1gSCjc4PhfS=>				NXi4RpJpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{NCCWR1mgQUA{Njl6MUC3JO69VS5?	NHXme2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
COLON	NYTD[ZVHSW62aYT1cY9zKGG\|c3H5		MX20PEBpenN?		NFT4c3lCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygWGdKKD1iMz65PFExPyEQvF2u	MnPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
COLON	M2rLb2FvfGm2dX3vdkBie3OjeR?=				MnizRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgZ49td25idIXtc5Ih[2WubIOsJHRIUSB;IEOuPVgyODdizszNMi=>	NF3xUoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
central nervous system cancer cells	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=				M4jCWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINmdnS{YXygcoVzfm:3czDzfZN1\W1iY3HuZ4VzKGOnbHzzMEBVT0liPTC2MlMxQTV5IN88UU4>	M3m2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
prostate cancer cells	MkDhR5l1d3SxeHnjbZR6KGG\|c3H5				MnvtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{NCCWR1mgQUA3NjNyOUW3JO69VS5?	NY\UZ3lSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
CNS	Mlj5RY51cXS3bX;yJIF{e2G7		M4HHWlQ5KGi{cx?=		MULBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFTmOgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKFSJSTC9JFYvOzB7NUeg{txONg>?	NFLYc4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
prostate cancer cells	MXjBcpRqfHWvb4KgZZN{[Xl?		NVvD[ZJvPDhiaILz		M3nmUmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIIDyc5N1[XSnIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC2MlMxQTV5IN88UU4>	NHrYNIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
CNS	NHn1dWVCdnSrdIXtc5Ih[XO\|YYm=				MWjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDDUnMhfHWvb4KgZ4VtdHNuIGTHTUA:KDZwM{C5OVch\|ryPLh?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
prostate cancer cells	NHLTUYRCdnSrdIXtc5Ih[XO\|YYm=				Mn2wRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgdJJwe3SjdHWgeJVud3JiY3XscJMtKFSJSTC9JFYvOzB7NUeg{txONg>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
prostate cancer cells	Ml;sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4SxXlQ5KGi{cx?=		Ml3yS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iNj6zNUDPxE1w	MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
CNS	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MV[0PEBpenN?		MlXPS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gR25UKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMtKFSJSTC9JFYvOzFizszNMi=>	NUjKZmNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
CNS	NF3oOGVEgXSxdH;4bYNqfHliYYPzZZk>		MlzEOFghcHK\|		NWLscVVpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDZwM{Gg{txONg>?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
prostate cancer cells	NWPxW5dpS3m2b4TvfIlkcXS7IHHzd4F6		MV20PEBpenN?		Mlr1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iNj6zNUDPxE1w	M{fvcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
prostate cancer cells	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=		NW\NUnl6PDhiaILz		NUDweZpwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gOk4{OSEQvF2u	M{TCWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
CNS	MkH5R5l1d3SxeHnjbZR6KGG\|c3H5		M3L2R\|Q5KGi{cx?=		NIjCUINEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEVlNiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hPi5\|MTFOwG0v	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Melanoma cells	M3jG[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkT0OFghcHK\|		M{TIXGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gO{46PCEQvF2u	M{LlW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
breast cancer cells	MlXkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NW\tWYoxPDhiaILz		M4j4Umdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB5Lkm0JO69VS5?	NYTtR2VpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
breast cancer cells	MmLlR5l1d3SxeHnjbZR6KGG\|c3H5		M{SyTFQ5KGi{cx?=		NXm4R2NzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
Melanoma cells	MnzkR5l1d3SxeHnjbZR6KGG\|c3H5		M4DsTlQ5KGi{cx?=		NYThTJJ6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdWWuYX7vcYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUA4Njl2IN88UU4>	NGfiWVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
Melanoma cells	Mo\hR5l1d3SxeHnjbZR6KGG\|c3H5		NG\3bVI1QCCqcoO=		M12zWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gO{46PCEQvF2u	MmXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
breast cancer cells	MYjDfZRwfG:6aXPpeJkh[XO\|YYm=		MmPDOFghcHK\|		NUSwZpYxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEeuPVQh\|ryPLh?=	M1;m[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
Melanoma cells	NGXmcHJCdnSrdIXtc5Ih[XO\|YYm=		NXnOPIVLPDhiaILz		M{P5TmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3lcIFvd22jIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKFSJSTC9JFcvQTR\|Mkig{txONg>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Melanoma cells	MmO0R5l1d3SxeHnjbZR6KGG\|c3H5				M3L1VGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|LDDUS2khRSB5Lkm0N\|I5KM7:TT6=	NEDhRpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
breast cancer cells	MoHwR5l1d3SxeHnjbZR6KGG\|c3H5				NEn0c3lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{NCCWR1mgQUA4Njl2M{K4JO69VS5?	M4rGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
breast cancer cells	NELxTmJCdnSrdIXtc5Ih[XO\|YYm=		MkfpOFghcHK\|		NUOyWYJ{SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC3Mlk1OzJ6IN88UU4>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Melanoma cells	M2DjfWFvfGm2dX3vdkBie3OjeR?=				MoLBRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcYVt[W6xbXGgZ4VtdHNuIGTHTUA:KDdwOUSzNlgh\|ryPLh?=	NX71Wo9sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
breast tumor cells	NUDDU\|FNSW62aYT1cY9zKGG\|c3H5				MoPURY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgZpJm[XO2IIT1cY9zKGOnbHzzMEBVT0liPTC3Mlk1OzJ6IN88UU4>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
NSCLC	NVjtNVZwSW62aYT1cY9zKGG\|c3H5				NHT2bGpCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBPW0OOQzDj[YxteyxiVFfJJF0hOTVwOES4PUDPxE1w	NVLVUWI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
Leukemia cells	MUHBcpRqfHWvb4KgZZN{[Xl?		Moe2OFghcHK\|		NYTCWGF3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUIV2c2WvaXGgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiVFfJJF0hOTVwOES4PUDPxE1w	M3q5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
NSCLC	NH7keI1CdnSrdIXtc5Ih[XO\|YYm=		Mm\ZOFghcHK\|		MmjWRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTmPDUGMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygWGdKKD1iMUWuPFQ5QSEQvF2u	NWLVVpNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
Non-small cell lung carcinoma cells	M1\2[2N6fG:2b4jpZ4l1gSCjc4PhfS=>				MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOc44ue22jbHygZ4VtdCCudX7nJINiemOrbn;tZUBk\WyuczygWGdKKD1iMUWuPFQ5QSEQvF2u	NFjwbYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
Leukemia cells	MnnaR5l1d3SxeHnjbZR6KGG\|c3H5				MorKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcIV2c2WvaXGgZ4VtdHNuIGTHTUA:KDF3Lki0PFkh\|ryPLh?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
Leukemia cells	MVjBcpRqfHWvb4KgZZN{[Xl?				MmnjRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcIV2c2WvaXGgZ4VtdHNuIGTHTUA:KDF3Lki0PFkh\|ryPLh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
NSCLC	NY\LOFNNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF\OfnM1QCCqcoO=		M2rT[Gdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUWuPFUh\|ryPLh?=	M4HZVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
Leukemia cells	M1P6OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoS3OFghcHK\|		NEPrV3VIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBt\XWtZX3pZUBk\WyuczDh[pRmeiB2ODDodpMtKFSJSTC9JFE2Njh3IN88UU4>	MmLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
NSCLC	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=		MV[0PEBpenN?		Mn7IR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzNT64OUDPxE1w	MmXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
Leukemia cells	NHe2b2lEgXSxdH;4bYNqfHliYYPzZZk>		M3vkXFQ5KGi{cx?=		NX\0bpVmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUAyPS56NTFOwG0v	M13CdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
NSCLC	NUnxO2l3S3m2b4TvfIlkcXS7IHHzd4F6		MUS0PEBpenN?		M1vwN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUWuPFUh\|ryPLh?=	NGDsZlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
Leukemia cells	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=		MWS0PEBpenN?		M2LVS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gNVUvQDVizszNMi=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
renal cancer cells	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUi0PEBpenN?		NHT4XGNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBz\W6jbDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzOT65OUDPxE1w	NF7EdZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
ovarian cancer cells	NVP2[opiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4XuOlQ5KGi{cx?=		M1HMfWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG93[XKrYX6gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUmuPVUh\|ryPLh?=	NXe2SI0zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
renal cancer cells	MmnjR5l1d3SxeHnjbZR6KGG\|c3H5		MonkOFghcHK\|		NF;KOoJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBz\W6jbDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzOT65OUDPxE1w	NHPJcms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0O\|c1QSd-MkS3OFc4PDl:L3G+
ovarian cancer cells	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		NFnVTpA1QCCqcoO=		NF7lfVlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBwfmG{aXHuJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEG5Mlk2KM7:TT6=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
renal cancer cells	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		MVK0PEBpenN?		M3jEcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF7Lkm1JO69VS5?	NFG4SXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
ovarian cancer cells	M{PIO2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MnLwOFghcHK\|		NFey[3NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBwfmG{aXHuJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEG5Mlk2KM7:TT6=	NW\mUnB2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
ovarian cancer cells	M{DVOWN6fG:2b4jpZ4l1gSCjc4PhfS=>				NHXWcGFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBwfmG{aXHuJINidmOncjDj[YxteyxiVFfJJF0hOTlwOUWyOkDPxE1w	NYHae2xvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
renal cancer cells	NETmXYdEgXSxdH;4bYNqfHliYYPzZZk>				MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOsJHRIUSB;IEG5Mlk2OjZizszNMi=>	NYftU29qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1PVgxOThpPkG4OVk5ODF6PD;hQi=>
ovarian cancer cells	NFjlc2tCdnSrdIXtc5Ih[XO\|YYm=		NU\nSZNbPDhiaILz		M4rhfGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIH;2ZZJq[W5iY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJHRIUSB;IEG5Mlk2OjZizszNMi=>	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
renal cancer cells	M1;YVWFvfGm2dX3vdkBie3OjeR?=		M{CwRVQ5KGi{cx?=		MkHvRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icnXuZYwh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIGTHTUA:KDF7Lkm1NlYh\|ryPLh?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
renal tumor cells	MkG4RY51cXS3bX;yJIF{e2G7				MXjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDy[Y5idCC2dX3vdkBk\WyuczygWGdKKD1iMUmuPVUzPiEQvF2u	NUfOXWU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
ovarian tumor cells	M3zxeWFvfGm2dX3vdkBie3OjeR?=				M3;S[mFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI93[XKrYX6geJVud3JiY3XscJMtKFSJSTC9JFE6Njl3Mk[g{txONg>?	NFKxZYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
PC3	NW\YXnBSS3m2b4TvfIlkcXS7IHHzd4F6		NXX2bIR6PDhiaILz		MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOjhwMUGg{txONg>?	MmLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NVYoRjJ7MUe0PFE3RC:jPh?=
neural precursor cells	MlrZSpVv[3Srb36gZZN{[Xl?				NYDjVHBSUW6qaXLpeIlwdiCxZjDu[ZVzd3OyaHXy[UBxem:uaX\ldoF1cW:wIH;mJI1wfXOnIH7leZJidCCycnXjeZJ{d3JiY3XscJMh[nliTWTUJIF{e2G7	NE\mOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxO\|Y{OSd-MUe0NVc3OzF:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; PubMed: 26156322 J Hematol Oncol MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine	26156322
Growth inhibition assay	Cell viability ; PubMed: 26156322 J Hematol Oncol MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively. Cell viability was measured by MTT assay.	26156322

体内研究

Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠，平均生长延迟120天和52天以上，且再植指数分别为0.06％和5％。^[5] Vincristine 处理小鼠，通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量，降低近75%。^[6]

细胞实验：^[1]	- 合并 Cell lines: B16 黑色素瘤细胞 Concentrations: 10 nM Incubation Time: 3 天 Method: 细胞按5 × 10⁴ cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上，在37°C下含5% CO₂ 和95% 空气的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基，继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后，每天使用库氏计数器完成细胞计数 (Only for Reference)
动物实验：^[5]	- 合并 Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠 Dosages: 3 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： Saline	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Vincristine (NSC-67574) sulfate SDF

分子量	923.04
化学式	C₄₆H₅₈N₄O₁₄S
CAS号	2068-78-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Leurocristine, Oncovin, 22-Oxovincaleukoblastine

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04448834	Not yet recruiting	Drug: Blinatumomab	B-cell Acute Lymphoblastic Leukemia	David Rizzieri MD\|Amgen\|Acrotech Biopharma LLC\|Duke University	April 1 2021	Phase 2
NCT03981510	Recruiting	Diagnostic Test: 3D-Transit	Constipation\|Childhood Acute Lymphoblastic Leukemia\|Neurofibromatosis 1\|Chronic Constipation With Overflow	University of Aarhus	June 13 2019	Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
回答：
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

研究领域

产品类型

定制您的化合物库

Vincristine (NSC-67574) sulfate

客户使用Selleck生产的Vincristine (NSC-67574) sulfate发表文献89篇：

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Vincristine (NSC-67574) sulfate SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法